MariTide: the once-monthly weight-loss injection

TL;DR

• MariTide is Amgen's investigational once-monthly obesity injectable - not approved, not available, currently in Phase 3.
• The mechanism is biologically counterintuitive: it activates GLP-1 while blocking GIP - the opposite of tirzepatide, which activates GIP.
• Phase 2 produced weight loss exceeding 20–24%, placing it among the more potent injectable candidates alongside retatrutide.
• Monthly dosing is the real story - roughly 12 administrations a year instead of 52, and persistence is the single biggest predictor of long-term results.
• Its peptide-antibody conjugate design is what gives it the long duration in the body that makes monthly administration possible.
• Gastrointestinal effects apply as across the class, and the side-effect pattern under monthly administration is still being characterised.

Educational content, not medical advice. No doses or protocols appear. MariTide is investigational and not approved.

---

MariTide (Amgen's obesity candidate) stands out in the pipeline for two reasons. First, dosing: it's designed for monthly - or even less frequent - administration, a meaningful adherence advantage over weekly injections. Second, mechanism: it's a GLP-1 receptor agonist combined with a GIP receptor antagonist - which is intriguing, because tirzepatide is a GIP agonist. That two different approaches to GIP both aid weight loss is one of the field's genuine puzzles. In Phase 2, MariTide produced weight loss exceeding 20%, and it's now in Phase 3. Here's the honest read.

What it is and how it works

MariTide is an investigational monthly injectable that combines:

• GLP-1 receptor agonism - the familiar appetite-suppressing lever
• GIP receptor antagonism - blocking GIP, rather than activating it

This is the counterintuitive part. Tirzepatide succeeds by activating GIP; MariTide blocks it - and both produce strong weight loss. The likely explanation is that GIP biology is complex and context-dependent, and there may be more than one way to exploit it. MariTide's design as a peptide-antibody conjugate is also what enables its long duration in the body, and therefore the monthly dosing.

The data

In its Phase 2 program, MariTide delivered weight loss exceeding 20–24% - placing it among the more potent injectable candidates, alongside retatrutide. It has moved into Phase 3. As with all pipeline agents, Phase 2 numbers can shift in larger, longer pivotal trials, and full head-to-head comparisons don't yet exist.

Why monthly dosing matters

Adherence is a real-world efficacy problem: weekly injections mean roughly 52 doses a year to remember and tolerate. A monthly (or less frequent) schedule cuts that dramatically, which could improve persistence - the single biggest predictor of long-term results. Longer intervals may also smooth the side-effect experience for some people, though that has to be borne out in the larger trials.

Side effects and trade-offs

• Gastrointestinal - nausea and vomiting, as across the class; the monthly-dosing side-effect pattern is still being characterised.
• Investigational - Phase 3 safety and durability data are still being generated.
• Muscle - like all rapid weight loss, lean-mass protection applies.

Where it stands

MariTide is not approved and not available. It's in Phase 3, so it sits behind the filed candidates (like CagriSema) on the timeline. It's a "watch this space" drug - notable less for beating the efficacy ceiling than for potentially changing the experience of treatment through monthly dosing.

The bottom line - and where to start

MariTide's promise is convenience with potency: a monthly injection producing 20%+ weight loss, via an unusual GLP-1-agonist/GIP-antagonist mechanism. It's investigational and in Phase 3 - a reason to be interested in where dosing frequency is heading, not a product to wait for when effective weekly options exist now under supervision.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore tirzepatide.

Frequently asked questions

What is MariTide? An investigational once-monthly obesity injectable from Amgen combining GLP-1 receptor agonism with GIP receptor antagonism. It produced over 20% weight loss in Phase 2 and is now in Phase 3. It's not approved.

How is MariTide different from Mounjaro? Both involve GIP, but oppositely: tirzepatide (Mounjaro) activates GIP, while MariTide blocks it - and both drive weight loss. MariTide is also designed for monthly, rather than weekly, dosing.

When will MariTide be available? It's in Phase 3, so it sits behind the nearer-term filed candidates; availability depends on trial outcomes and review. It is not available now.

Related reading

• New weight-loss drugs 2026–2027 · Tirzepatide · Retatrutide · Ultra-long-acting monthly GLP-1s
• Part of The Complete Guide to GLP-1s

---

Educational content, not medical advice. MariTide is investigational and not approved; trial data and timelines change. Claims for the Malaysian market are subject to MAB requirements.

References

• MariTide (Amgen): investigational monthly injectable; GLP-1 receptor agonist + GIP receptor antagonist (peptide-antibody conjugate); Phase 2 weight loss exceeding ~20–24%; now in Phase 3. · GLP-1 class gastrointestinal profile.